Company Press Releases

Patient Groups Sharpen Their Capabilities to Protect Access to Medicines for Treating Rare Bleeding Disorders

2017-09-28 / @newswire

KING OF PRUSSIA, Pa., Sept. 28, 2017 /PRNewswire/ -- The Great Lakes Hemophilia Foundation (GLHF) headquartered in Milwaukee, Wis., the New York City Hemophilia Chapter (NYCHC) and the Ohio Bleeding Disorders Council (OBDC) in Columbus take on complex legislative and public policy issues to ensur...Read More

Comstock Drills 1.25 m at 220.96 g/t Gold and 4.20 m at 17.40 g/t Gold at North Zone, Preview Project, Saskatchewan

2017-09-28 / @thenewswire

(TheNewswire) Vancouver, BC / TheNewswire / September 28, 2017 - Comstock Metals Ltd. (TSX-V: CSL) ("Comstock" or the "Company") is pleased to report partial results from the summer diamond drilling program at its 100% owned Preview SW gold project located 40 km northeast of La Ronge, Saskatche...Read More

Japan's Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment

2017-09-28 / @newswire

TOKYO, Sept. 28, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved AFSTYLA (R) (hereafter AFSTYLA) [lonoctocog alfa] a recombinant single-chain coagulation factor VIII (rVIII-SingleChain) in...Read More

CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State

2017-09-19 / @newswire

UNIVERSITY PARK, Pa., Sept. 19, 2017 /PRNewswire/ -- Penn State today announced that CSL Behring, a global specialty biotherapeutics leader, has committed $4.92 million to Penn State over the next six years to create the multidisciplinary Center of Excellence in Biotechnology, and to revitalize...Read More

Comstock Commences Drilling at QV Gold Project, White Gold District, Yukon

2017-09-15 / @nasdaq

VANCOUVER, British Columbia, Sept.15, 2017(GLOBE NEWSWIRE) -- Comstock Metals Ltd. (TSX-V:CSL) ("Comstock" or the "Company") is pleased to announce that it has commenced a core drilling program on its 100% owned QV gold project located in the heart of the prolific White Gold district of the Yuko...Read More

CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI

2017-09-14 / @newswire

EDINBURGH, United Kingdom, Sept. 14, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that its "Join Together" campaign at the 2017 European Society for Immunodeficiencies (ESID) meeting has resulted in a ?,?15,000 donation to IPOPI, the International Patient Organis...Read More

CSL Behring Announces FDA Approval of Privigen (R) [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults

2017-09-14 / @newswire

KING OF PRUSSIA, Pa., Sept. 14, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen (R) [Immune Globulin Intravenous (Human), 10% Liquid] for the treatment of adults with chronic inflammatory demyeli...Read More

Comstock Confirms Termination of Proposed Sale of Comstock Shares by Select Sands Corp.

2017-09-13 / @nasdaq

VANCOUVER, British Columbia, Sept.12, 2017(GLOBE NEWSWIRE) -- Comstock Metals Ltd. (TSX-V:CSL) ("Comstock" or the "Company") announced today that it has been advised that the offer made by SJ Strategic Investments, LLC, Gracetree Investments, LLC, Gregory Asset Partners, LLC and the Gregory Irre...Read More

Canadian Parents Willing to Vaccinate Their Infants with Adjuvanted Influenza Vaccine, Study Finds

2017-09-11 / @businesswire

Canadian parents who are educated about immunizing their infants against influenza with an adjuvanted trivalent influenza vaccine (aTIV) see it as a wise, effective, and safe choice. But public-funding status can greatly influence their opinions and intentions to actually immunize children wi...Read More

New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQIV)

2017-09-11 / @businesswire

Annual influenza-related pediatric hospitalizations in Canada have ranged from about 700 to 1,500 during the last five influenza seasons, and a total of nearly 50 influenza-related paediatric deaths have occurred across that time span, according to the Canadian government.1 One potential solu...Read More

Comstock Confirms Further Extension of Offer Deadline

2017-09-08 / @nasdaq

VANCOUVER, British Columbia, Sept.07, 2017(GLOBE NEWSWIRE) -- Comstock Metals Ltd. (TSX-V:CSL) ("Comstock" or the "Company") announced today that it has been advised that the deadline for Select Sands Corp. to respond to the previously disclosed offer made by SJ Strategic Investments, LLC, Grace...Read More

Comstock Confirms Extension of Offer Deadline

2017-09-06 / @nasdaq

VANCOUVER, British Columbia, Sept.06, 2017(GLOBE NEWSWIRE) -- Comstock Metals Ltd. (TSX-V:CSL) ("Comstock" or the "Company") announced today that it has been advised that the deadline for Select Sands Corp. to respond to the offer made by SJ Strategic Investments, LLC, Gracetree Investments, LLC...Read More

Comstock Confirms Review of Proposed Share Sale

2017-09-05 / @marketwired

VANCOUVER, BC--(Marketwired - September 05, 2017) - Comstock Metals Ltd. (TSX VENTURE: CSL) ("Comstock" or the "Company") announced today that it is reviewing the offer made by SJ Strategic Investments, LLC, Gracetree Investments, LLC, Gregory Asset Partners, LLC and the Gregory Irrevocable Eq...Read More

SJ Strategic Investments, LLC, Gracetree Investments, LLC, Gregory Asset Partners, LLC and the Gregory Irrevocable Equalizing Trust, acting jointly Files Early Warning Report

2017-09-01 / @newswire

VANCOUVER, British Columbia, Sept. 1, 2017 /PRNewswire/ -- SJ Strategic Investments, LLC, Gracetree Investments, LLC, Gregory Asset Partners, LLC and the Gregory Irrevocable Equalizing Trust, acting jointly (collectively the "Syndicate"), announced that they have filed an early warning report in...Read More

SJ Strategic Investments, LLC, Gracetree Investments, LLC, Gregory Asset Partners, LLC and the Gregory Irrevocable Equalizing Trust, acting jointly Files Early Warning Report

2017-09-01 / @newswire

VANCOUVER, Sept. 1, 2017 /CNW/ - SJ Strategic Investments, LLC, Gracetree Investments, LLC, Gregory Asset Partners, LLC and the Gregory Irrevocable Equalizing Trust, acting jointly (collectively the "Syndicate"), announced that they have filed an early warning report in respect of an offer (the "...Read More

CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform

2017-08-28 / @newswire

KING OF PRUSSIA, Pa., Aug. 28, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Calimmune, Inc., a biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, Ca...Read More

Comstock Completes Summer Drilling Program at Preview SW Gold Project, Saskatchewan

2017-08-24 / @marketwired

VANCOUVER, BC--(Marketwired - August 24, 2017) - Comstock Metals Ltd. (TSX VENTURE: CSL) ("Comstock" or the "Company") is pleased to announce that it has completed the previously announced summer exploration program at its 100% owned Preview SW gold project, located 40 km northeast of La Ronge,...Read More

Berinert (R) Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients

2017-08-09 / @newswire

OTTAWA, Canada, Aug. 9, 2017 /CNW/ -- CSL Behring is pleased to announce that on March 31st, 2017 Berinert (C1 Esterase Inhibitor, Human) was approved by Heath Canada for Pediatric Hereditary Angioedema (HAE). "HAE is an unpredictable and life threatening disease with few treatment options appr...Read More

HAEGARDA (R) (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema

2017-07-25 / @newswire

KING OF PRUSSIA, Pa., July 25, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that HAEGARDA (R) (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in the United States. The U.S. Food and Drug Administration (FDA) approved HAEGARDA on June 22, 2017...Read More

CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA (R) (C1 Esterase Inhibitor Subcutaneous [Human])

2017-07-21 / @newswire

KING OF PRUSSIA, Pa., July 21, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven years of orphan-drug exclusivity for HAEGARDA (R) (C1 Esterase Inhibitor Subcutaneous [Human]), the first and...Read More

Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok